Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

Core Insights - Allogene Therapeutics (NASDAQ: ALLO) has been under observation since May 2020, following the release of data from their Phase I ALPHA study concerning ALLO-501 for relapsed/refractory non-Hodgkin lymphoma (NHL) [1] Group 1 - The company focuses on innovative therapies and pharmaceuticals that have potential catalysts for acquisitions [1]